Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Verona Pharma plc
  6. Summary
    VRNA   US9250501064

VERONA PHARMA PLC

(VRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
5.05(c) 4.98(c) 5.11(c) 5.25(c) 5.14 Last
56 013 18 384 23 224 52 766 25 126 Volume
+1.41% -1.39% +2.61% +2.74% -2.10% Change
More quotes
Estimated financial data (e)
Sales 2021 2,99 M 4,11 M 4,11 M
Net income 2021 -66,3 M -91,0 M -91,0 M
Net cash position 2021 105 M 145 M 145 M
P/E ratio 2021 -4,62x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -79,9 M -110 M -110 M
Net cash position 2022 29,2 M 40,1 M 40,1 M
P/E ratio 2022 -4,59x
Yield 2022 -
Capitalization 225 M 309 M 309 M
EV / Sales 2021 39,9x
EV / Sales 2022 -
Nbr of Employees 26
Free-Float 93,8%
More Financials
Company
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. The Company's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The Company is... 
More about the company
Ratings of Verona Pharma plc
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about VERONA PHARMA PLC
10/26VERONA PHARMA : to Report Third Quarter 2021 Financial Results and Provide Corporate Updat..
AQ
10/20European ADRs Move Slightly Higher in Wednesday Trading
MT
10/15European ADRs Move Higher in Friday Trading
MT
10/14European ADRs Climb Higher in Thursday Trading
MT
10/13European ADRs Move Higher in Wednesday Trading
MT
10/13VERONA PHARMA : to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
GL
10/13Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
CI
10/08European ADRs Move Higher in Friday Trading
MT
10/07European ADRs Climb Higher in Thursday Trading
MT
10/06European ADRs Move Lower in Wednesday Trading
MT
10/01European ADRs Move Lower in Friday Trading
MT
09/30European ADRs Move Higher in Thursday Trading
MT
09/28European ADRs Decline in Tuesday Trading
MT
09/22European ADRs Climb Higher in Wednesday Trading
MT
09/21European ADRs Move Higher in Tuesday Trading
MT
More news
News in other languages on VERONA PHARMA PLC
10/20Les ADR européens progressent légèrement dans les échanges de mercredi
10/15Les ADR européens sont en hausse vendredi
10/14Les ADR européens grimpent dans la journée de jeudi
10/13Les ADR européens sont en hausse mercredi
10/08Les ADR européens sont en hausse vendredi
More news
Chart VERONA PHARMA PLC
Duration : Period :
Verona Pharma plc Technical Analysis Chart | VRNA | US9250501064 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,14 $
Average target price 20,00 $
Spread / Average Target 289%
EPS Revisions
Managers and Directors
David S. Zaccardelli President, CEO & Executive Director
Mark W. Hahn Chief Financial Officer
David Raymond Ebsworth Non-Executive Chairman
Kathleen Rickard Chief Medical Officer
Tara Rheault Vice President-Research & Development Operations
Sector and Competitors
1st jan.Capi. (M$)
VERONA PHARMA PLC-25.00%315
GILEAD SCIENCES, INC.14.61%84 921
BIONTECH SE241.97%70 618
WUXI APPTEC CO., LTD.20.76%64 231
REGENERON PHARMACEUTICALS22.04%61 565
VERTEX PHARMACEUTICALS-23.44%47 753